Weinberger v. Hynson, Westcott & Dunning, Inc. (1972)
- Docket
- 72-394
- Decided
- 1972-01-01
- Public Good score
- 75 / 100
- Framers' Intent score
- 64 / 100
Summary
Weinberger v. Hynson, Westcott & Dunning, Inc. is a dispute between the federal official responsible for administering the Food and Drug Administration and a drug manufacturer, arising out of the FDA’s authority under the 1962 amendments to the Federal Food, Drug, and Cosmetic Act governing the approval and continued marketing of prescription drugs. From the limited oral-argument record available, the consolidated cases generally concerned how the 1962 amendments changed the premarketing review regime from a focus on “safety” alone to a more demanding framework, but the specific drug, agency action, and administrative record are not provided. The key legal question appears to have involved the scope of FDA power and the evidentiary showing required of manufacturers under the post-1962 statutory standards, yet the precise Question Presented and the Court’s merits holding and reasoning are not available in the supplied sources and the case is identified as pending. As a result, while the case likely carried broader implications for administrative law and federal drug regulation—particularly the standards for demonstrating a drug’s qualifications for approval or continued sale—its concrete doctrinal impact cannot be stated accurately without the Supreme Court’s decision.
Case Brief
Facts
Not available in sources. The available oral-argument excerpt indicates the case was part of a set of “five consolidated cases” involving “important questions under the 1962 amendments to the Federal Food, Drug & Cosmetic law,” and that counsel characterized the pre-1962 regime as limiting FDA premarketing review to drug “safety.” Beyond that high-level description, the specific underlying facts about Hynson, Westcott & Dunning, Inc., the drug(s) involved, the FDA action taken, and the administrative record are not available in the provided sources. Not available in sources. Not available in sources.
Procedural History
The case came to the Supreme Court from the United States Court of Appeals for the Fourth Circuit. The matter was argued as part of a group of consolidated cases referenced by Chief Justice Burger (including docket numbers 72-395, 72-414, 72-528, 72-555, and 72-666). The specific judgment of the Fourth Circuit (including whether it affirmed/reversed an FDA action and the reasoning) is not available in the provided sources. Not available in sources.
Issue
Not available in sources (the oral-argument excerpt refers generally to “important questions under the 1962 amendments to the Federal Food, Drug & Cosmetic law,” but does not provide the exact Question Presented).
Holding
Not available in sources. The user-provided status indicates “pending,” and no Supreme Court merits disposition, vote count, or holding is included in the provided materials. Not available in sources.
Rule
Not available in sources. The excerpt suggests the case concerned the legal standards for FDA premarketing clearance under the 1962 Federal Food, Drug & Cosmetic Act amendments (as contrasted with the prior focus on “safety”), but no adopted Supreme Court rule/test is provided in the supplied sources.
Reasoning
Not available in sources. While the excerpt frames the controversy as involving interpretation of the 1962 amendments to the Federal Food, Drug & Cosmetic Act and contrasts them with the predecessor statute’s focus on “safety,” it does not include the Court’s analysis, any constitutional provisions, statutory construction, or precedent relied upon. Not available in sources. Not available in sources. Not available in sources.
Significance
Not available in sources. Based on the excerpt alone, the case appears to have addressed FDA authority and standards for new-drug approval under the 1962 amendments, which could be significant for administrative law and food-and-drug regulation, but the actual impact and doctrinal significance cannot be stated accurately without the Court’s decision. Not available in sources. Not available in sources.
Public Good Analysis
GPT: The decision reinforced the FDA’s authority to require substantial evidence of safety and efficacy before approving drugs, supporting public health and consumer protection. By upholding rigorous administrative screening of New Drug Applications and limiting end-runs around scientific standards, it likely reduced the risk of ineffective or dangerous drugs reaching the market while promoting trust in regulatory oversight. | Claude: This decision upheld the FDA's authority to require pharmaceutical companies to prove drug effectiveness through adequate and well-controlled studies, protecting public health by ensuring drugs on the market are both safe and effective. The ruling benefits consumers by preventing the marketing of ineffective medications and strengthens scientific standards in drug approval, though it may increase costs and regulatory burden on pharmaceutical development.
Framers' Intent Analysis
GPT: The ruling aligns moderately with the framers’ acceptance of Congress creating executive enforcement structures to implement enumerated powers, consistent with Madison’s view in Federalist No. 51 that separated branches must have adequate means to perform their functions. However, its strong deference to modern administrative expertise sits somewhat in tension with the framers’ limited-government and anti-consolidation concerns voiced by Jefferson and by Montesquieu’s separation-of-powers theory, since broad delegations to agencies were not a central feature of the founding design. | Claude: The decision reflects the framers' acceptance of administrative expertise in technical matters, consistent with the necessary and proper clause and Congress's broad commerce power. While the framers valued limited government, they also recognized the need for regulatory authority in areas requiring specialized knowledge. The deference to agency expertise aligns with the practical governance philosophy of framers like Hamilton, though strict constructionists like Jefferson might have viewed this administrative power with more skepticism regarding delegation of legislative authority.